Abruzzo G K, Flattery A M, Gill C J, Kong L, Smith J G, Krupa D, Pikounis V B, Kropp H, Bartizal K
Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA.
Antimicrob Agents Chemother. 1995 May;39(5):1077-81. doi: 10.1128/AAC.39.5.1077.
The activities of the water-soluble pneumocandin derivatives L-733560, L-705589, and L-731373 were evaluated in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis and were compared with those of commercially available antifungal agents. Pneumocandins are inhibitors of 1,3-beta-D-glucan synthesis. In the aspergillosis model, L-733560 and L-705589 significantly prolonged the survival of DBA/2N mice challenged intravenously with Aspergillus fumigatus conidia. L-733560 and L-705589 exhibited efficacies comparable to that of amphotericin B (AMB) with 90% effective doses of 0.48, 0.12, and 0.36 mg/kg of body weight, respectively. Two mouse models of disseminated candidiasis were used to evaluate these compounds. In both models, mice were challenged intravenously with Candida albicans. In a C. albicans survival model with DBA/2N and CD-1 mice, the efficacy of L-733560 was comparable to that of AMB, while L-731373 and L-705589 were somewhat less active. In a previously described C. albicans target organ kidney assay, the pneumocandin analogs and AMB at doses of > or = 0.09 mg/kg were effective in sterilizing kidneys, while fluconazole and ketoconazole were considerably less active and did not sterilize kidneys when they were used at concentrations of < or = 100 mg/kg. Although orally administered L-733560 showed activity in both candidiasis models, its efficacy was reduced compared with that of parenterally administered drug. In a disseminated cryptococcosis mouse model that measures the number of CFU of Cryptococcus neoformans per gram of brain and spleen, L-733560 at 10 mg/kg was ineffective in reducing the counts in organs, while AMB at 0.31 mg/kg sterilized the organs. These results indicate that the pneumocandins may be beneficial as potent parenterally administered therapeutic agents for disseminated aspergillosis and candidiasis.
在播散性曲霉病、念珠菌病和隐球菌病的小鼠模型中评估了水溶性棘白菌素衍生物L-733560、L-705589和L-731373的活性,并与市售抗真菌药物的活性进行了比较。棘白菌素是1,3-β-D-葡聚糖合成的抑制剂。在曲霉病模型中,L-733560和L-705589显著延长了经静脉注射烟曲霉分生孢子攻击的DBA/2N小鼠的存活时间。L-733560和L-705589表现出与两性霉素B(AMB)相当的疗效,其90%有效剂量分别为0.48、0.12和0.36mg/kg体重。使用两种播散性念珠菌病小鼠模型评估这些化合物。在这两种模型中,小鼠均经静脉注射白色念珠菌。在白色念珠菌存活模型中,对于DBA/2N和CD-1小鼠,L-733560的疗效与AMB相当,而L-731373和L-705589的活性稍低。在先前描述的白色念珠菌靶器官肾脏试验中,剂量≥0.09mg/kg的棘白菌素类似物和AMB可有效使肾脏无菌,而氟康唑和酮康唑活性明显较低,当以≤100mg/kg的浓度使用时不能使肾脏无菌。尽管口服L-733560在两种念珠菌病模型中均表现出活性,但其疗效与胃肠外给药的药物相比有所降低。在一个测量每克脑和脾中新型隐球菌CFU数量的播散性隐球菌病小鼠模型中,10mg/kg的L-733560在降低器官中的菌数方面无效,而0.31mg/kg的AMB可使器官无菌。这些结果表明,棘白菌素作为胃肠外给药的强效治疗药物,可能对播散性曲霉病和念珠菌病有益。